ProfileGDS5678 / 1433590_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 53% 54% 54% 55% 54% 53% 53% 53% 55% 55% 54% 55% 54% 54% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.3418853
GSM967853U87-EV human glioblastoma xenograft - Control 23.3460154
GSM967854U87-EV human glioblastoma xenograft - Control 33.3280354
GSM967855U87-EV human glioblastoma xenograft - Control 43.3246355
GSM967856U87-EV human glioblastoma xenograft - Control 53.2983154
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.3842753
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.367553
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3071853
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3382855
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3373955
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.3338754
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.3358855
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3348954
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3400554